These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
336 related articles for article (PubMed ID: 24376747)
1. CXCR2-driven ovarian cancer progression involves upregulation of proinflammatory chemokines by potentiating NF-κB activation via EGFR-transactivated Akt signaling. Dong YL; Kabir SM; Lee ES; Son DS PLoS One; 2013; 8(12):e83789. PubMed ID: 24376747 [TBL] [Abstract][Full Text] [Related]
2. NF-κB-Mediated CCL20 Reigns Dominantly in CXCR2-Driven Ovarian Cancer Progression. Ignacio RM; Kabir SM; Lee ES; Adunyah SE; Son DS PLoS One; 2016; 11(10):e0164189. PubMed ID: 27723802 [TBL] [Abstract][Full Text] [Related]
3. Inhibitory effect of tumor suppressor p53 on proinflammatory chemokine expression in ovarian cancer cells by reducing proteasomal degradation of IκB. Son DS; Kabir SM; Dong YL; Lee E; Adunyah SE PLoS One; 2012; 7(12):e51116. PubMed ID: 23300534 [TBL] [Abstract][Full Text] [Related]
4. Interleukin-1 beta transactivates epidermal growth factor receptor via the CXCL1-CXCR2 axis in oral cancer. Lee CH; Syu SH; Liu KJ; Chu PY; Yang WC; Lin P; Shieh WY Oncotarget; 2015 Nov; 6(36):38866-80. PubMed ID: 26462152 [TBL] [Abstract][Full Text] [Related]
5. GRO-α and IL-8 enhance ovarian cancer metastatic potential via the CXCR2-mediated TAK1/NFκB signaling cascade. Yung MM; Tang HW; Cai PC; Leung TH; Ngu SF; Chan KK; Xu D; Yang H; Ngan HY; Chan DW Theranostics; 2018; 8(5):1270-1285. PubMed ID: 29507619 [TBL] [Abstract][Full Text] [Related]
6. Epithelial-stromal communication via CXCL1-CXCR2 interaction stimulates growth of ovarian cancer cells through p38 activation. Park GY; Pathak HB; Godwin AK; Kwon Y Cell Oncol (Dordr); 2021 Feb; 44(1):77-92. PubMed ID: 32910411 [TBL] [Abstract][Full Text] [Related]
7. A key role for early growth response-1 and nuclear factor-kappaB in mediating and maintaining GRO/CXCR2 proliferative signaling in esophageal cancer. Wang B; Khachigian LM; Esau L; Birrer MJ; Zhao X; Parker MI; Hendricks DT Mol Cancer Res; 2009 May; 7(5):755-64. PubMed ID: 19435811 [TBL] [Abstract][Full Text] [Related]
8. Keratinocyte chemoattractant (KC)/human growth-regulated oncogene (GRO) chemokines and pro-inflammatory chemokine networks in mouse and human ovarian epithelial cancer cells. Son DS; Parl AK; Rice VM; Khabele D Cancer Biol Ther; 2007 Aug; 6(8):1302-12. PubMed ID: 17712227 [TBL] [Abstract][Full Text] [Related]
9. Chemokine-cytokine cross-talk. The ELR+ CXC chemokine LIX (CXCL5) amplifies a proinflammatory cytokine response via a phosphatidylinositol 3-kinase-NF-kappa B pathway. Chandrasekar B; Melby PC; Sarau HM; Raveendran M; Perla RP; Marelli-Berg FM; Dulin NO; Singh IS J Biol Chem; 2003 Feb; 278(7):4675-86. PubMed ID: 12468547 [TBL] [Abstract][Full Text] [Related]
10. Levo-corydalmine alleviates vincristine-induced neuropathic pain in mice by inhibiting an NF-kappa B-dependent CXCL1/CXCR2 signaling pathway. Zhou L; Hu Y; Li C; Yan Y; Ao L; Yu B; Fang W; Liu J; Li Y Neuropharmacology; 2018 Jun; 135():34-47. PubMed ID: 29518397 [TBL] [Abstract][Full Text] [Related]
11. CXCL1/GROα increases cell migration and invasion of prostate cancer by decreasing fibulin-1 expression through NF-κB/HDAC1 epigenetic regulation. Kuo PL; Shen KH; Hung SH; Hsu YL Carcinogenesis; 2012 Dec; 33(12):2477-87. PubMed ID: 23027620 [TBL] [Abstract][Full Text] [Related]
12. Hepatocyte growth factor (HGF) upregulates heparanase expression via the PI3K/Akt/NF-κB signaling pathway for gastric cancer metastasis. Hao NB; Tang B; Wang GZ; Xie R; Hu CJ; Wang SM; Wu YY; Liu E; Xie X; Yang SM Cancer Lett; 2015 May; 361(1):57-66. PubMed ID: 25727320 [TBL] [Abstract][Full Text] [Related]
13. Crosstalk between NFκB-dependent astrocytic CXCL1 and neuron CXCR2 plays a role in descending pain facilitation. Ni H; Wang Y; An K; Liu Q; Xu L; Zhu C; Deng H; He Q; Wang T; Xu M; Zheng Y; Huang B; Fang J; Yao M J Neuroinflammation; 2019 Jan; 16(1):1. PubMed ID: 30606213 [TBL] [Abstract][Full Text] [Related]
14. CXCL5 induces tumor angiogenesis via enhancing the expression of FOXD1 mediated by the AKT/NF-κB pathway in colorectal cancer. Chen C; Xu ZQ; Zong YP; Ou BC; Shen XH; Feng H; Zheng MH; Zhao JK; Lu AG Cell Death Dis; 2019 Feb; 10(3):178. PubMed ID: 30792394 [TBL] [Abstract][Full Text] [Related]
15. Snail promotes ovarian cancer progression by recruiting myeloid-derived suppressor cells via CXCR2 ligand upregulation. Taki M; Abiko K; Baba T; Hamanishi J; Yamaguchi K; Murakami R; Yamanoi K; Horikawa N; Hosoe Y; Nakamura E; Sugiyama A; Mandai M; Konishi I; Matsumura N Nat Commun; 2018 Apr; 9(1):1685. PubMed ID: 29703902 [TBL] [Abstract][Full Text] [Related]
16. Opposite regulation by PI3K/Akt and MAPK/ERK pathways of tissue factor expression, cell-associated procoagulant activity and invasiveness in MDA-MB-231 cells. Hu C; Huang L; Gest C; Xi X; Janin A; Soria C; Li H; Lu H J Hematol Oncol; 2012 Jul; 5():16. PubMed ID: 22534171 [TBL] [Abstract][Full Text] [Related]
17. The chemokine CXCL1 induces proliferation in epithelial ovarian cancer cells by transactivation of the epidermal growth factor receptor. Bolitho C; Hahn MA; Baxter RC; Marsh DJ Endocr Relat Cancer; 2010 Dec; 17(4):929-40. PubMed ID: 20702723 [TBL] [Abstract][Full Text] [Related]
18. A positive feedback loop involving EGFR/Akt/mTORC1 and IKK/NF-kB regulates head and neck squamous cell carcinoma proliferation. Li Z; Yang Z; Passaniti A; Lapidus RG; Liu X; Cullen KJ; Dan HC Oncotarget; 2016 May; 7(22):31892-906. PubMed ID: 26895469 [TBL] [Abstract][Full Text] [Related]
19. Sanguinarine inhibits epithelial ovarian cancer development via regulating long non-coding RNA CASC2-EIF4A3 axis and/or inhibiting NF-κB signaling or PI3K/AKT/mTOR pathway. Zhang S; Leng T; Zhang Q; Zhao Q; Nie X; Yang L Biomed Pharmacother; 2018 Jun; 102():302-308. PubMed ID: 29571014 [TBL] [Abstract][Full Text] [Related]
20. Loss of SMAD4 Promotes Colorectal Cancer Progression by Recruiting Tumor-Associated Neutrophils via the CXCL1/8-CXCR2 Axis. Ogawa R; Yamamoto T; Hirai H; Hanada K; Kiyasu Y; Nishikawa G; Mizuno R; Inamoto S; Itatani Y; Sakai Y; Kawada K Clin Cancer Res; 2019 May; 25(9):2887-2899. PubMed ID: 30705034 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]